Detalhe da pesquisa
1.
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.
N Engl J Med
; 388(21): 1942-1955, 2023 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224196
2.
The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
Lancet
; 403(10436): 1554-1562, 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555928
3.
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Lancet
; 403(10426): 533-544, 2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310910
4.
Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers.
N Engl J Med
; 384(22): 2115-2123, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077644
5.
Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.
Clin Infect Dis
; 66(3): 387-395, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29020321
6.
A randomized, controlled trial of an aerosolized vaccine against measles.
N Engl J Med
; 372(16): 1519-29, 2015 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25875257
7.
MenAfriVac as an Antitetanus Vaccine.
Clin Infect Dis
; 61 Suppl 5: S570-7, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553690
8.
Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India.
Clin Infect Dis
; 61 Suppl 5: S483-8, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553678
9.
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons.
Clin Infect Dis
; 61 Suppl 5: S501-6, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553681
10.
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
Clin Infect Dis
; 61 Suppl 5: S507-13, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553682
11.
Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
Clin Infect Dis
; 61 Suppl 5: S554-62, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553688
12.
Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.
Clin Infect Dis
; 61 Suppl 5: S586-93, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553692
13.
Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine.
Clin Infect Dis
; 61 Suppl 5: S422-7, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553670
14.
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
Clin Infect Dis
; 61 Suppl 5: S514-20, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553683
15.
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Clin Infect Dis
; 61 Suppl 5: S521-30, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553684
16.
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
N Engl J Med
; 364(24): 2293-304, 2011 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21675889
17.
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.
Lancet Infect Dis
; 24(6): 639-649, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38408457
18.
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Hum Vaccin Immunother
; 20(1): 2304974, 2024 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38512394
19.
Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure.
Lancet Reg Health Southeast Asia
; 14: 100207, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37492421
20.
Post-marketing safety surveillance of the rotavirus vaccine in India.
Vaccine X
; 15: 100362, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37593522